RecruitingPhase 2NCT05983159
A Trial of Targeted Therapies for Patients With Slow-Flow or Fast-Flow Vascular Malformations
Studying Cystic hygroma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Murdoch Childrens Research Institute
- Principal Investigator
- Tony Penington, MBBS, FRACS.Study Principal Investigator
- Intervention
- Alpelisib(drug)
- Enrollment
- 50 enrolled
- Eligibility
- 2 years · All sexes
- Timeline
- 2024 – 2026
Study locations (2)
- Peter MacCallum Cancer Centre, Parkville, Victoria, Australia
- The Royal Children's Hospital, Parkville, Victoria, Australia
Collaborators
Peter MacCallum Cancer Centre, Australia · Royal Children's Hospital
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05983159 on ClinicalTrials.gov